Trial Profile

A phase 1 study of MB-204

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 21 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MB-204 (Primary)
Indications Alzheimer's disease; Depressive disorders; Hepatic fibrosis
Focus Adverse reactions

Most Recent Events

21 Sep 2023 New trial record
22 Aug 2023 According to a Marvel media release, the company has completed toxicological study and is preparing for FDA IND submission and a Phase 1 study in Australia and will report on the timing of the trial shortly. The company plans to engage with strategic partners sooner for this study.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com